From Morningstar: 2024-06-28 07:30:00

New weight loss drugs like Ozempic are boosting shares of manufacturers Novo Nordisk and Eli Lilly. The stocks are up over 80% and 97%, respectively. Experts predict the duopoly in the market will be hard to break, with both companies investing heavily in research, development, and preparing for the future.

GLP-1 drugs, initially for diabetes, are evolving rapidly, with potential for a larger market in the future. Novo Nordisk and Eli Lilly are leading the charge in developing new iterations. Competitors face challenges in breaking into the market due to the companies’ established trust with doctors and strong sales forces representing their drugs.



Read more at Morningstar: Why it Will be ‘Exceptionally Difficult’ to…